In a landmark study published in Science Advances, Vanderbilt researchers have created the first high-resolution lipid atlas of the human kidney, mapping over 100,000 functional tissue units across 29 donors. By integrating advanced imaging mass spectrometry with microscopy using machine learning, the team identified distinct lipid signatures that could transform diagnostics and precision treatments for kidney disease.

A new Concordia study published in Scientific Reports finds that aquatic therapy not only strengthens spinal muscles in people with chronic low back pain but also helps reduce pain-related fear and sleep disturbances. These results suggest that aquatic therapy may offer both physical and psychological benefits beyond standard care.

A University of Houston optometry professor, who has pioneered the method of wearing multifocal lenses to slow myopia, is now reporting the biological changes associated with slowing eye growth when wearing multifocal lenses.  

Suicide is the third leading cause of death among young adults. But for those with intellectual and developmental disabilities (IDD), the crisis is even worse.  A study highlights a critical yet overlooked public health crisis: the rising risk of suicide among young adults with IDD. Despite common misconceptions, individuals with IDD face heightened vulnerability due to social isolation, trauma, limited support, and systemic gaps in mental health care. The need for tailored prevention strategies is urgent to address this growing need.

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces the development of novel pan-KRAS inhibitors of new chemotypes through structure-based drug design, scaffold hopping combined with intense molecular modeling, empowered by the generative chemistry methods of Chemistry42, Insilico’s proprietary generative chemistry platform. Developed in the joint efforts of artificial intelligence and human expertise, the candidate compounds demonstrated pan-KRAS inhibition with potency in the upper nanomolar range. The results have been recently published on ACS Medicinal Chemistry Letters.